Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC) ; volume:9 ; number:1 ; day:27 ; month:8 ; year:2009 ; pages:1-17 ; date:12.2009
BMC cancer ; 9, Heft 1 (27.8.2009), 1-17, 12.2009
- Urheber
-
Glaysher, Sharon
- Beteiligte Personen und Organisationen
-
Yiannakis, Dennis
Gabriel, Francis G.
Johnson, Penny
Polak, Marta E.
Knight, Louise A.
Goldthorpe, Zoe
Peregrin, Katharine
Gyi, Mya
Modi, Paul
Rahamim, Joe
Smith, Mark E.
Amer, Khalid
Addis, Bruce
Poole, Matthew
Narayanan, Ajit
Gulliford, Tim J.
Andreotti, Peter E.
Cree, Ian A.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-9-300
- URN
-
urn:nbn:de:1111-2016030352592
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Glaysher, Sharon
- Yiannakis, Dennis
- Gabriel, Francis G.
- Johnson, Penny
- Polak, Marta E.
- Knight, Louise A.
- Goldthorpe, Zoe
- Peregrin, Katharine
- Gyi, Mya
- Modi, Paul
- Rahamim, Joe
- Smith, Mark E.
- Amer, Khalid
- Addis, Bruce
- Poole, Matthew
- Narayanan, Ajit
- Gulliford, Tim J.
- Andreotti, Peter E.
- Cree, Ian A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Author Correction: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC
LUBAC determines chemotherapy resistance in squamous cell lung cancer
MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Author Correction: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC
LUBAC determines chemotherapy resistance in squamous cell lung cancer
MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
Author Correction: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC
LUBAC determines chemotherapy resistance in squamous cell lung cancer